top of page
Cardiovascular
Health
CardioMetabolic
Health
Lung Health
Bone Health
All-in-one AI-CVD
Bundle
AutoFracture
(coming soon)
1 Non-Contrast Scan 10+ Actionable Reports
Grow Your Vision
Welcome visitors to your site with a short, engaging introduction.
Double click to edit and add your own text.
News and Updates
Cardiometabolic phenotyping from Coronary Artery Calcium (CAC) scans predicts obstructive and high-risk plaques on Coronary CT Angiography (CCTA): an AI-CVD study within Miami Heart Study
ESC Congress 2026 - 28 - 31 Aug 2026 Munich, Germany Organised by: European Society of Cardiology (ESC) visual Can a routine coronary calcium scan reveal high-risk coronary disease beyond the traditional calcium score? A HeartLung.AI AI-CVD study within the Miami Heart Study explores how comprehensive AI-based cardiometabolic phenotyping from routine Coronary Artery Calcium (CAC) scans can help identify important coronary plaque characteristics that are typically evaluated us
2 days ago2 min read
Agaston 2.0, A next-generation AI-based coronary calcium quantification approach to improve risk stratification among individuals with zero Agatston scores – Part I
ESC Congress 2026 - 28 - 31 Aug 2026 Munich, Germany Organised by: European Society of Cardiology (ESC) visual Is a coronary calcium score of zero truly zero? Presented at ESC Congress 2026, this HeartLung.AI study introduces Agatston-2.0, a next-generation AI-based approach designed to detect subtle coronary calcification that may be missed by conventional Agatston scoring. Traditional Agatston scoring has transformed cardiovascular risk assessment over the past three decade
2 days ago2 min read
Long-term Lung Cancer Risk Prediction Using Sybil AI on Routine Coronary Artery Calcium Scans
ESC Congress 2026 - 28 - 31 Aug 2026 Munich, Germany Organised by: European Society of Cardiology (ESC) visual Can a routine cardiac CT predict lung cancer risk years before diagnosis? A new HeartLung.AI study explores the potential of Sybil AI to predict long-term lung cancer risk using routine coronary artery calcium (CAC) scans. Using baseline CAC scans from 5,726 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), researchers evaluated incident lung cancer o
2 days ago1 min read
AI-Derived Left Atrial Volume Index,LA/RA and LA/LV Volume Ratios FromCoronary Artery Calcium (CAC) Scans PredictLong-Term Atrial Fibrillation and Stroke
ESC Congress 2026 - 28 - 31 Aug 2026 Munich, Germany Organised by: European Society of Cardiology (ESC) visual Can a routine coronary calcium scan reveal more about a patient’s long-term cardiovascular risk? A new HeartLung.AI study explores how AI-derived cardiac chamber measurements from routine coronary artery calcium (CAC) scans may help predict future atrial fibrillation and stroke. Using data from the MESA and Framingham Heart Study cohorts, researchers evaluated AI-der
2 days ago1 min read
Performance of Sybil AI for lung cancer risk assessment: a head-to-head comparison of cardiac vs. lung CT scans
ESC Congress 2026 - 28 - 31 Aug 2026 Munich, Germany Organised by: European Society of Cardiology (ESC) visual Can AI assess lung cancer risk from a cardiac CT—even when the entire lung isn’t visible? In this study, Sybil AI was evaluated head-to-head on cardiac coronary artery calcium (CAC) scans and full chest CT scans across 4,486 scans from the FHS and MESA cohorts. Despite the limited lung field of view, Sybil maintained strong lung cancer risk prediction on cardiac CT,
2 days ago1 min read
RSNA Features HeartLung.AI Study Linking AI-Quantified Myosteatosis to Future COPD Risk
20-year MESA analysis finds CT-derived muscle quality predicts COPD more strongly than emphysema-like lung measures. HOUSTON, Texas - August 7, 2026 - HeartLung.AI today announced that the Radiological Society of North America (RSNA) has featured a major research publication demonstrating the potential of artificial intelligence-derived myosteatosis measurements from coronary artery calcium (CAC) CT scans to predict future chronic obstructive pulmonary disease (COPD). The ded
Aug 74 min read
Low-Dose Imaging for Early Multi-disease Assessment & Prevention
Low-Dose Imaging for Early Multi-disease Assessment & Prevention is a nonprofit initiative established to advance one of the most ambitious preventive medicine programs ever proposed: the LDCT Mega Trial. The initiative envisions using a single low-dose, non-contrast CT scan combined with artificial intelligence to detect multiple life-threatening diseases before symptoms develop, fundamentally transforming the way preventive healthcare is delivered. The proposed LDCT Mega Tr
Aug 71 min read
Should We Screen Asymptomatic Patients with Coronary CT?
Coronary CT has become one of the most powerful imaging technologies for cardiovascular risk assessment. However, an important clinical question remains: Should Coronary CT Angiography (CCTA) be used routinely to screen asymptomatic individuals, or does Coronary Artery Calcium (CAC) scanning already provide sufficient information for preventive care? This presentation reviews the current evidence comparing CAC scoring and CCTA in primary prevention, examining their predictive
Jul 191 min read
Two HeartLung.AI Studies Show Routine Chest CT Can Assess Cardiac Risk Comparably to Dedicated Cardiac CT and Echocardiography
Complementary MESA analyses validate AI-derived cardiac chamber volumetry from non-gated, non-contrast CT for opportunistic heart failure and atrial fibrillation risk assessment HOUSTON - July 16, 2026 - HeartLung.AI announced the acceptance of two complementary studies in the American Journal of Preventive Cardiology demonstrating that artificial intelligence can extract clinically meaningful cardiac chamber measurements from routine non-gated, non-contrast chest CT and asse
Jul 164 min read
Vision 2030: Preventive Imaging Agentic AI
Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial Vision 2030 presents HeartLung.AI’s long-term vision for transforming medical imaging into a comprehensive, AI-powered preventive healthcare ecosystem. Rather than generating a diagnostic report alone, the platform is designed to convert a single medical image into a personalized prevention strategy that follows patients throughout their lives. The proposed Preventive Imaging Agentic AI framework integrates multiple in
Jul 151 min read
LDCT Mega Trial — Preventive Imaging Agentic AI vs. Usual Care
Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual Care The LDCT Mega Trial is an ambitious vision for one of the largest prospective clinical studies ever proposed in artificial intelligence, designed to evaluate whether an Agentic AI-powered preventive imaging ecosystem can improve long-term health outcomes compared with conventional medical care. The proposed randomized trial plans to enroll 100,000 participants across 250 cl
Jul 151 min read
AI-CVD: AI-Powered Cardiovascular Risk Assessment from CAC and Chest CT
Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group AI-CVD is an advanced artificial intelligence platform that transforms routine coronary artery calcium (CAC) and chest CT scans into comprehensive cardiovascular risk assessments by extracting a wide range of imaging biomarkers from a single examination. Rather than relying solely on traditional clinical risk factors, AI-CVD analyzes multiple cardiome
Jul 151 min read
AI-CAC: Coronary Plaque Analysis from Non-Contrast CT
AI-CAC introduces a novel artificial intelligence approach for coronary plaque analysis using non-contrast cardiac CT (CAC) scans, offering the potential to extract plaque characteristics traditionally obtainable only from contrast-enhanced coronary CT angiography (CCTA). Conventional CCTA provides excellent visualization of coronary anatomy but requires intravenous contrast administration and is affected by scanner-, software-, and observer-related variability. AI-CAC addres
Jul 151 min read
Agatston-2.0: A New Generation of AI-Based Coronary Calcium Analysis
Agatston-2.0 is a next-generation artificial intelligence framework developed to enhance cardiovascular risk assessment in individuals with Agatston coronary artery calcium (CAC) scores below 100—a population that represents nearly 75% of individuals undergoing CAC scanning and accounts for a substantial proportion of future coronary heart disease events. Rather than relying solely on conventional calcium scoring, Agatston-2.0 introduces advanced AI-derived biomarkers that an
Jul 151 min read
AutoLung AI: Expanding the Future of Lung Cancer Detection Beyond Traditional Screening
AutoLung AI is an advanced artificial intelligence platform designed to improve lung cancer detection and long-term risk prediction using a wide range of CT imaging studies—not only dedicated low-dose lung cancer screening CT, but also routine chest CT, coronary artery calcium (CAC) scans, and coronary CT angiography (CCTA). Unlike conventional approaches that primarily focus on pulmonary nodules, AutoLung AI integrates whole-lung imaging biomarkers with nodule-level analysis
Jul 151 min read
4th LDCT Mega Trial / LIFEMAP Study Design Meeting SCCT.26 - San Diego
Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group Meeting Objective: To review recent AI-CVD and Agatston-2.0 research progress, discuss the latest LDCT Mega Trial / LIFEMAP study design, evaluate key unresolved protocol questions, introduce LUNGevity as a potential nonprofit administrative and advocacy partner, and begin discussion of funding sources and fundraising plans. 1. Opening Remarks Dr. Mo
Jul 84 min read
HeartLung Launches "Why Pay More and Get Less?" Campaign at SCCT 2026
Campaign contrasts coronary plaque-centric AI-CCTA marketing with AI-CVD's CAC-based, whole-patient primary prevention approach: one lower-cost, lower-radiation, non-contrast CT scan, 10+ actionable reports, and broader cardiovascular and cardiometabolic risk phenotyping. SAN DIEGO, July 6, 2026 - HeartLung Corporation (HeartLung.AI), a medical AI company transforming CT imaging into preventive care intelligence, today announced the launch of its "Why Pay More and Get Less?"
Jul 75 min read
AHA Stroke Alert Podcast Features HeartLung.AI Research on AI-Predicted Atrial Fibrillation and Stroke
AI-derived left atrial volume and chamber ratios from CAC scans predicted long-term AF and stroke in MESA and Framingham. HOUSTON, June 18, 2026 - HeartLung.AI today announced that its research article, "AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke," was featured on the June 2026 episode of the Stroke Alert Podcast, the podcast of Stroke, a journal of the American Heart Associatio
Jun 193 min read
After 36 Years, the Legendary Agatston Score Gets Its First Major AI Upgrade
New peer-reviewed study introduces Agatston-2.0, led by Morteza Naghavi, MD, with Arthur S. Agatston, MD, the originator of the original Agatston score, and leading cardiovascular imaging and prevention experts. HOUSTON, TX, June 2026 — HeartLung Corporation today announced the publication of a landmark peer-reviewed study introducing Agatston-2.0, a next-generation artificial intelligence-based coronary artery calcium scoring method designed to modernize one of the most infl
Jun 127 min read
Study Shows AI-CVD® Outperforms Diabetes in Predicting Heart Failure Risk
HOUSTON, TX, May 18, 2026 - HeartLung Corporation announced the publication of a new study in the American Journal of Preventive Cardiology titled “Comparing Incidence of Heart Failure in Individuals with Enlarged Cardiac Chambers versus Diabetes.” The study demonstrates that HeartLung’s AI-CVD AutoChamber module can opportunistically identify left atrial enlargement, left ventricular enlargement, and increased left ventricular mass from routine coronary artery calcium scans,
May 184 min read
HeartLung.AI Emerges as a Leading Innovator in Cardiology with 10 Accepted ESC.26 Abstracts
Accepted studies showcase HeartLung.AI’s leadership in AI-CVD, opportunistic CT screening, Agatston 2.0, chamber volumetry, and preventive cardiology. HOUSTON, Texas, 05/11/2026 – HeartLung.AI today announced that 10 scientific abstracts have been accepted for presentation at ESC Congress 2026, the annual meeting of the European Society of Cardiology. The accepted studies showcase HeartLung.AI’s growing leadership in AI–enabled cardiovascular imaging and preventive cardiology
May 118 min read
Updates from 'X' (Twitter)
Ready to Unlock the Value in Your CT Scans?
Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.
bottom of page